Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone vs Vitamin E in NASH (PIVENS)
NCT00063622Phase 3Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Jan 2005
- Primary completion
- Jun 2009
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) comparing Pioglitazone, Vitamin E and Placebo (3 arms). Primary endpoint: Improvement in Non-alcoholic Fatty Liver Disease (NAFLD) Activity Defined by Change in Standardized Scoring of Liver Biopsies at 96 weeks. Started Jan 2005; status: completed.
02
Drugs
pioglitazonevitamin e
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT00063622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063622.